Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497753 | 1.00 | ROCK2 (0.48) | ROCK2RORCPOLBKDRF2 | |
| SCHEMBL4501476 | 0.91 | ROCK2 (0.42) | ROCK2POLBF2PLGPLAU | |
| SCHEMBL4501472 | 0.91 | ROCK2 (0.42) | ROCK2POLBF2PLGPLAU | |
| SCHEMBL226773 | 0.87 | POLB (0.46) | ROCK2POLBKLKB1TSHRSIRT2 | |
| SCHEMBL226772 | 0.87 | POLB (0.46) | ROCK2POLBKLKB1TSHRSIRT2 | |
| SCHEMBL10293630 | 0.87 | MAP2K1 (0.40) | ROCK2POLBKMT2A | |
| SCHEMBL10325117 | 0.87 | MAP2K1 (0.40) | ROCK2POLBKMT2A | |
| SCHEMBL10370855 | 0.87 | ROCK2 (0.39) | ROCK2 | |
| SCHEMBL4491081 | 0.86 | ROCK2 (0.37) | ROCK2SIGMAR1TMEM97KMT2A | |
| SCHEMBL4491083 | 0.86 | ROCK2 (0.37) | ROCK2SIGMAR1TMEM97KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | ROCK2 392/4885RORC 309/4885POLB 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.